img

Global Antihemophilic Factor Drug Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Antihemophilic Factor Drug Market Insights, Forecast to 2034

Antihemophilic Factor Drug is used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). It is also used in these patients before surgery to prevent bleeding.
Global Antihemophilic Factor Drug market is expected to reach to US$ 558 million in 2024, with a positive growth of %, compared with US$ 541 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Antihemophilic Factor Drug industry is evaluated to reach US$ 796 million in 2029. The CAGR will be 6.1% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Antihemophilic Factor Drug market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Antihemophilic Factor Drug market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Bayer
Takeda
Novo Nordisk
Pfizer
Grifols
CSL Behring
Sanofi
Cigna
Octapharma
GC Pharma
Hualan Biological Engineering
Shanghai RAAS blood products
Segment by Type
250 IU
500 IU
1000 IU
1500 IU
2000 IU
3000 IU
4000 IU
Other potencies

Segment by Application


Adult
Pediatric

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Antihemophilic Factor Drug plant distribution, commercial date of Antihemophilic Factor Drug, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Antihemophilic Factor Drug introduction, etc. Antihemophilic Factor Drug Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Antihemophilic Factor Drug
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Antihemophilic Factor Drug Product Introduction
1.2 Market by Type
1.2.1 Global Antihemophilic Factor Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 250 IU
1.2.3 500 IU
1.2.4 1000 IU
1.2.5 1500 IU
1.2.6 2000 IU
1.2.7 3000 IU
1.2.8 4000 IU
1.2.9 Other potencies
1.3 Market by Application
1.3.1 Global Antihemophilic Factor Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Adult
1.3.3 Pediatric
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Antihemophilic Factor Drug Sales Estimates and Forecasts 2018-2029
2.2 Global Antihemophilic Factor Drug Revenue by Region
2.2.1 Global Antihemophilic Factor Drug Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Antihemophilic Factor Drug Revenue by Region (2018-2024)
2.2.3 Global Antihemophilic Factor Drug Revenue by Region (2024-2029)
2.2.4 Global Antihemophilic Factor Drug Revenue Market Share by Region (2018-2029)
2.3 Global Antihemophilic Factor Drug Sales Estimates and Forecasts 2018-2029
2.4 Global Antihemophilic Factor Drug Sales by Region
2.4.1 Global Antihemophilic Factor Drug Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Antihemophilic Factor Drug Sales by Region (2018-2024)
2.4.3 Global Antihemophilic Factor Drug Sales by Region (2024-2029)
2.4.4 Global Antihemophilic Factor Drug Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Antihemophilic Factor Drug Sales by Manufacturers
3.1.1 Global Antihemophilic Factor Drug Sales by Manufacturers (2018-2024)
3.1.2 Global Antihemophilic Factor Drug Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Antihemophilic Factor Drug in 2022
3.2 Global Antihemophilic Factor Drug Revenue by Manufacturers
3.2.1 Global Antihemophilic Factor Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Antihemophilic Factor Drug Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Antihemophilic Factor Drug Revenue in 2022
3.3 Global Key Players of Antihemophilic Factor Drug, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Antihemophilic Factor Drug Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Antihemophilic Factor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Antihemophilic Factor Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Antihemophilic Factor Drug, Product Offered and Application
3.8 Global Key Manufacturers of Antihemophilic Factor Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Antihemophilic Factor Drug Sales by Type
4.1.1 Global Antihemophilic Factor Drug Historical Sales by Type (2018-2024)
4.1.2 Global Antihemophilic Factor Drug Forecasted Sales by Type (2024-2029)
4.1.3 Global Antihemophilic Factor Drug Sales Market Share by Type (2018-2029)
4.2 Global Antihemophilic Factor Drug Revenue by Type
4.2.1 Global Antihemophilic Factor Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Antihemophilic Factor Drug Forecasted Revenue by Type (2024-2029)
4.2.3 Global Antihemophilic Factor Drug Revenue Market Share by Type (2018-2029)
4.3 Global Antihemophilic Factor Drug Price by Type
4.3.1 Global Antihemophilic Factor Drug Price by Type (2018-2024)
4.3.2 Global Antihemophilic Factor Drug Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Antihemophilic Factor Drug Sales by Application
5.1.1 Global Antihemophilic Factor Drug Historical Sales by Application (2018-2024)
5.1.2 Global Antihemophilic Factor Drug Forecasted Sales by Application (2024-2029)
5.1.3 Global Antihemophilic Factor Drug Sales Market Share by Application (2018-2029)
5.2 Global Antihemophilic Factor Drug Revenue by Application
5.2.1 Global Antihemophilic Factor Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Antihemophilic Factor Drug Forecasted Revenue by Application (2024-2029)
5.2.3 Global Antihemophilic Factor Drug Revenue Market Share by Application (2018-2029)
5.3 Global Antihemophilic Factor Drug Price by Application
5.3.1 Global Antihemophilic Factor Drug Price by Application (2018-2024)
5.3.2 Global Antihemophilic Factor Drug Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Antihemophilic Factor Drug Market Size by Type
6.1.1 US & Canada Antihemophilic Factor Drug Sales by Type (2018-2029)
6.1.2 US & Canada Antihemophilic Factor Drug Revenue by Type (2018-2029)
6.2 US & Canada Antihemophilic Factor Drug Market Size by Application
6.2.1 US & Canada Antihemophilic Factor Drug Sales by Application (2018-2029)
6.2.2 US & Canada Antihemophilic Factor Drug Revenue by Application (2018-2029)
6.3 US & Canada Antihemophilic Factor Drug Market Size by Country
6.3.1 US & Canada Antihemophilic Factor Drug Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Antihemophilic Factor Drug Sales by Country (2018-2029)
6.3.3 US & Canada Antihemophilic Factor Drug Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Antihemophilic Factor Drug Market Size by Type
7.1.1 Europe Antihemophilic Factor Drug Sales by Type (2018-2029)
7.1.2 Europe Antihemophilic Factor Drug Revenue by Type (2018-2029)
7.2 Europe Antihemophilic Factor Drug Market Size by Application
7.2.1 Europe Antihemophilic Factor Drug Sales by Application (2018-2029)
7.2.2 Europe Antihemophilic Factor Drug Revenue by Application (2018-2029)
7.3 Europe Antihemophilic Factor Drug Market Size by Country
7.3.1 Europe Antihemophilic Factor Drug Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Antihemophilic Factor Drug Sales by Country (2018-2029)
7.3.3 Europe Antihemophilic Factor Drug Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Antihemophilic Factor Drug Market Size
8.1.1 China Antihemophilic Factor Drug Sales (2018-2029)
8.1.2 China Antihemophilic Factor Drug Revenue (2018-2029)
8.2 China Antihemophilic Factor Drug Market Size by Application
8.2.1 China Antihemophilic Factor Drug Sales by Application (2018-2029)
8.2.2 China Antihemophilic Factor Drug Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Antihemophilic Factor Drug Market Size by Type
9.1.1 Asia Antihemophilic Factor Drug Sales by Type (2018-2029)
9.1.2 Asia Antihemophilic Factor Drug Revenue by Type (2018-2029)
9.2 Asia Antihemophilic Factor Drug Market Size by Application
9.2.1 Asia Antihemophilic Factor Drug Sales by Application (2018-2029)
9.2.2 Asia Antihemophilic Factor Drug Revenue by Application (2018-2029)
9.3 Asia Antihemophilic Factor Drug Sales by Region
9.3.1 Asia Antihemophilic Factor Drug Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Antihemophilic Factor Drug Revenue by Region (2018-2029)
9.3.3 Asia Antihemophilic Factor Drug Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Antihemophilic Factor Drug Market Size by Type
10.1.1 Middle East, Africa and Latin America Antihemophilic Factor Drug Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Antihemophilic Factor Drug Market Size by Application
10.2.1 Middle East, Africa and Latin America Antihemophilic Factor Drug Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Antihemophilic Factor Drug Sales by Country
10.3.1 Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Antihemophilic Factor Drug Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Bayer
11.1.1 Bayer Company Information
11.1.2 Bayer Overview
11.1.3 Bayer Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Bayer Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bayer Recent Developments
11.2 Takeda
11.2.1 Takeda Company Information
11.2.2 Takeda Overview
11.2.3 Takeda Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Takeda Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Takeda Recent Developments
11.3 Novo Nordisk
11.3.1 Novo Nordisk Company Information
11.3.2 Novo Nordisk Overview
11.3.3 Novo Nordisk Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Novo Nordisk Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Novo Nordisk Recent Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Overview
11.4.3 Pfizer Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Pfizer Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Pfizer Recent Developments
11.5 Grifols
11.5.1 Grifols Company Information
11.5.2 Grifols Overview
11.5.3 Grifols Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 Grifols Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Grifols Recent Developments
11.6 CSL Behring
11.6.1 CSL Behring Company Information
11.6.2 CSL Behring Overview
11.6.3 CSL Behring Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 CSL Behring Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 CSL Behring Recent Developments
11.7 Sanofi
11.7.1 Sanofi Company Information
11.7.2 Sanofi Overview
11.7.3 Sanofi Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.7.4 Sanofi Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sanofi Recent Developments
11.8 Cigna
11.8.1 Cigna Company Information
11.8.2 Cigna Overview
11.8.3 Cigna Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.8.4 Cigna Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Cigna Recent Developments
11.9 Octapharma
11.9.1 Octapharma Company Information
11.9.2 Octapharma Overview
11.9.3 Octapharma Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.9.4 Octapharma Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Octapharma Recent Developments
11.10 GC Pharma
11.10.1 GC Pharma Company Information
11.10.2 GC Pharma Overview
11.10.3 GC Pharma Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.10.4 GC Pharma Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 GC Pharma Recent Developments
11.11 Hualan Biological Engineering
11.11.1 Hualan Biological Engineering Company Information
11.11.2 Hualan Biological Engineering Overview
11.11.3 Hualan Biological Engineering Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.11.4 Hualan Biological Engineering Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Hualan Biological Engineering Recent Developments
11.12 Shanghai RAAS blood products
11.12.1 Shanghai RAAS blood products Company Information
11.12.2 Shanghai RAAS blood products Overview
11.12.3 Shanghai RAAS blood products Antihemophilic Factor Drug Sales, Price, Revenue and Gross Margin (2018-2024)
11.12.4 Shanghai RAAS blood products Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Shanghai RAAS blood products Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Antihemophilic Factor Drug Industry Chain Analysis
12.2 Antihemophilic Factor Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Antihemophilic Factor Drug Production Mode & Process
12.4 Antihemophilic Factor Drug Sales and Marketing
12.4.1 Antihemophilic Factor Drug Sales Channels
12.4.2 Antihemophilic Factor Drug Distributors
12.5 Antihemophilic Factor Drug Customers
13 Market Dynamics
13.1 Antihemophilic Factor Drug Industry Trends
13.2 Antihemophilic Factor Drug Market Drivers
13.3 Antihemophilic Factor Drug Market Challenges
13.4 Antihemophilic Factor Drug Market Restraints
14 Key Findings in The Global Antihemophilic Factor Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Antihemophilic Factor Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of 250 IU
Table 3. Major Manufacturers of 500 IU
Table 4. Major Manufacturers of 1000 IU
Table 5. Major Manufacturers of 1500 IU
Table 6. Major Manufacturers of 2000 IU
Table 7. Major Manufacturers of 3000 IU
Table 8. Major Manufacturers of 4000 IU
Table 9. Major Manufacturers of Other potencies
Table 10. Global Antihemophilic Factor Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 11. Global Antihemophilic Factor Drug Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 12. Global Antihemophilic Factor Drug Revenue by Region (2018-2024) & (US$ Million)
Table 13. Global Antihemophilic Factor Drug Revenue by Region (2024-2029) & (US$ Million)
Table 14. Global Antihemophilic Factor Drug Revenue Market Share by Region (2018-2024)
Table 15. Global Antihemophilic Factor Drug Revenue Market Share by Region (2024-2029)
Table 16. Global Antihemophilic Factor Drug Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 17. Global Antihemophilic Factor Drug Sales by Region (2018-2024) & (K Units)
Table 18. Global Antihemophilic Factor Drug Sales by Region (2024-2029) & (K Units)
Table 19. Global Antihemophilic Factor Drug Sales Market Share by Region (2018-2024)
Table 20. Global Antihemophilic Factor Drug Sales Market Share by Region (2024-2029)
Table 21. Global Antihemophilic Factor Drug Sales by Manufacturers (2018-2024) & (K Units)
Table 22. Global Antihemophilic Factor Drug Sales Share by Manufacturers (2018-2024)
Table 23. Global Antihemophilic Factor Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 24. Global Antihemophilic Factor Drug Revenue Share by Manufacturers (2018-2024)
Table 25. Global Key Players of Antihemophilic Factor Drug, Industry Ranking, 2021 VS 2022 VS 2024
Table 26. Antihemophilic Factor Drug Price by Manufacturers 2018-2024 (USD/Unit)
Table 27. Global Antihemophilic Factor Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Antihemophilic Factor Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihemophilic Factor Drug as of 2022)
Table 29. Global Key Manufacturers of Antihemophilic Factor Drug, Manufacturing Base Distribution and Headquarters
Table 30. Global Key Manufacturers of Antihemophilic Factor Drug, Product Offered and Application
Table 31. Global Key Manufacturers of Antihemophilic Factor Drug, Date of Enter into This Industry
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Antihemophilic Factor Drug Sales by Type (2018-2024) & (K Units)
Table 34. Global Antihemophilic Factor Drug Sales by Type (2024-2029) & (K Units)
Table 35. Global Antihemophilic Factor Drug Sales Share by Type (2018-2024)
Table 36. Global Antihemophilic Factor Drug Sales Share by Type (2024-2029)
Table 37. Global Antihemophilic Factor Drug Revenue by Type (2018-2024) & (US$ Million)
Table 38. Global Antihemophilic Factor Drug Revenue by Type (2024-2029) & (US$ Million)
Table 39. Global Antihemophilic Factor Drug Revenue Share by Type (2018-2024)
Table 40. Global Antihemophilic Factor Drug Revenue Share by Type (2024-2029)
Table 41. Antihemophilic Factor Drug Price by Type (2018-2024) & (USD/Unit)
Table 42. Global Antihemophilic Factor Drug Price Forecast by Type (2024-2029) & (USD/Unit)
Table 43. Global Antihemophilic Factor Drug Sales by Application (2018-2024) & (K Units)
Table 44. Global Antihemophilic Factor Drug Sales by Application (2024-2029) & (K Units)
Table 45. Global Antihemophilic Factor Drug Sales Share by Application (2018-2024)
Table 46. Global Antihemophilic Factor Drug Sales Share by Application (2024-2029)
Table 47. Global Antihemophilic Factor Drug Revenue by Application (2018-2024) & (US$ Million)
Table 48. Global Antihemophilic Factor Drug Revenue by Application (2024-2029) & (US$ Million)
Table 49. Global Antihemophilic Factor Drug Revenue Share by Application (2018-2024)
Table 50. Global Antihemophilic Factor Drug Revenue Share by Application (2024-2029)
Table 51. Antihemophilic Factor Drug Price by Application (2018-2024) & (USD/Unit)
Table 52. Global Antihemophilic Factor Drug Price Forecast by Application (2024-2029) & (USD/Unit)
Table 53. US & Canada Antihemophilic Factor Drug Sales by Type (2018-2024) & (K Units)
Table 54. US & Canada Antihemophilic Factor Drug Sales by Type (2024-2029) & (K Units)
Table 55. US & Canada Antihemophilic Factor Drug Revenue by Type (2018-2024) & (US$ Million)
Table 56. US & Canada Antihemophilic Factor Drug Revenue by Type (2024-2029) & (US$ Million)
Table 57. US & Canada Antihemophilic Factor Drug Sales by Application (2018-2024) & (K Units)
Table 58. US & Canada Antihemophilic Factor Drug Sales by Application (2024-2029) & (K Units)
Table 59. US & Canada Antihemophilic Factor Drug Revenue by Application (2018-2024) & (US$ Million)
Table 60. US & Canada Antihemophilic Factor Drug Revenue by Application (2024-2029) & (US$ Million)
Table 61. US & Canada Antihemophilic Factor Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 62. US & Canada Antihemophilic Factor Drug Revenue by Country (2018-2024) & (US$ Million)
Table 63. US & Canada Antihemophilic Factor Drug Revenue by Country (2024-2029) & (US$ Million)
Table 64. US & Canada Antihemophilic Factor Drug Sales by Country (2018-2024) & (K Units)
Table 65. US & Canada Antihemophilic Factor Drug Sales by Country (2024-2029) & (K Units)
Table 66. Europe Antihemophilic Factor Drug Sales by Type (2018-2024) & (K Units)
Table 67. Europe Antihemophilic Factor Drug Sales by Type (2024-2029) & (K Units)
Table 68. Europe Antihemophilic Factor Drug Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Antihemophilic Factor Drug Revenue by Type (2024-2029) & (US$ Million)
Table 70. Europe Antihemophilic Factor Drug Sales by Application (2018-2024) & (K Units)
Table 71. Europe Antihemophilic Factor Drug Sales by Application (2024-2029) & (K Units)
Table 72. Europe Antihemophilic Factor Drug Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Antihemophilic Factor Drug Revenue by Application (2024-2029) & (US$ Million)
Table 74. Europe Antihemophilic Factor Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 75. Europe Antihemophilic Factor Drug Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Antihemophilic Factor Drug Revenue by Country (2024-2029) & (US$ Million)
Table 77. Europe Antihemophilic Factor Drug Sales by Country (2018-2024) & (K Units)
Table 78. Europe Antihemophilic Factor Drug Sales by Country (2024-2029) & (K Units)
Table 79. China Antihemophilic Factor Drug Sales by Type (2018-2024) & (K Units)
Table 80. China Antihemophilic Factor Drug Sales by Type (2024-2029) & (K Units)
Table 81. China Antihemophilic Factor Drug Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Antihemophilic Factor Drug Revenue by Type (2024-2029) & (US$ Million)
Table 83. China Antihemophilic Factor Drug Sales by Application (2018-2024) & (K Units)
Table 84. China Antihemophilic Factor Drug Sales by Application (2024-2029) & (K Units)
Table 85. China Antihemophilic Factor Drug Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Antihemophilic Factor Drug Revenue by Application (2024-2029) & (US$ Million)
Table 87. Asia Antihemophilic Factor Drug Sales by Type (2018-2024) & (K Units)
Table 88. Asia Antihemophilic Factor Drug Sales by Type (2024-2029) & (K Units)
Table 89. Asia Antihemophilic Factor Drug Revenue by Type (2018-2024) & (US$ Million)
Table 90. Asia Antihemophilic Factor Drug Revenue by Type (2024-2029) & (US$ Million)
Table 91. Asia Antihemophilic Factor Drug Sales by Application (2018-2024) & (K Units)
Table 92. Asia Antihemophilic Factor Drug Sales by Application (2024-2029) & (K Units)
Table 93. Asia Antihemophilic Factor Drug Revenue by Application (2018-2024) & (US$ Million)
Table 94. Asia Antihemophilic Factor Drug Revenue by Application (2024-2029) & (US$ Million)
Table 95. Asia Antihemophilic Factor Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 96. Asia Antihemophilic Factor Drug Revenue by Region (2018-2024) & (US$ Million)
Table 97. Asia Antihemophilic Factor Drug Revenue by Region (2024-2029) & (US$ Million)
Table 98. Asia Antihemophilic Factor Drug Sales by Region (2018-2024) & (K Units)
Table 99. Asia Antihemophilic Factor Drug Sales by Region (2024-2029) & (K Units)
Table 100. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales by Type (2018-2024) & (K Units)
Table 101. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales by Type (2024-2029) & (K Units)
Table 102. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Type (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Type (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales by Application (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales by Application (2024-2029) & (K Units)
Table 106. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Application (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Application (2024-2029) & (US$ Million)
Table 108. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 109. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Country (2018-2024) & (US$ Million)
Table 110. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue by Country (2024-2029) & (US$ Million)
Table 111. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales by Country (2018-2024) & (K Units)
Table 112. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales by Country (2024-2029) & (K Units)
Table 113. Bayer Company Information
Table 114. Bayer Description and Major Businesses
Table 115. Bayer Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 116. Bayer Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. Bayer Recent Developments
Table 118. Takeda Company Information
Table 119. Takeda Description and Major Businesses
Table 120. Takeda Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 121. Takeda Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Takeda Recent Developments
Table 123. Novo Nordisk Company Information
Table 124. Novo Nordisk Description and Major Businesses
Table 125. Novo Nordisk Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 126. Novo Nordisk Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Novo Nordisk Recent Developments
Table 128. Pfizer Company Information
Table 129. Pfizer Description and Major Businesses
Table 130. Pfizer Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 131. Pfizer Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. Pfizer Recent Developments
Table 133. Grifols Company Information
Table 134. Grifols Description and Major Businesses
Table 135. Grifols Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 136. Grifols Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Grifols Recent Developments
Table 138. CSL Behring Company Information
Table 139. CSL Behring Description and Major Businesses
Table 140. CSL Behring Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 141. CSL Behring Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. CSL Behring Recent Developments
Table 143. Sanofi Company Information
Table 144. Sanofi Description and Major Businesses
Table 145. Sanofi Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 146. Sanofi Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Sanofi Recent Developments
Table 148. Cigna Company Information
Table 149. Cigna Description and Major Businesses
Table 150. Cigna Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 151. Cigna Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. Cigna Recent Developments
Table 153. Octapharma Company Information
Table 154. Octapharma Description and Major Businesses
Table 155. Octapharma Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 156. Octapharma Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. Octapharma Recent Developments
Table 158. GC Pharma Company Information
Table 159. GC Pharma Description and Major Businesses
Table 160. GC Pharma Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 161. GC Pharma Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 162. GC Pharma Recent Developments
Table 163. Hualan Biological Engineering Company Information
Table 164. Hualan Biological Engineering Description and Major Businesses
Table 165. Hualan Biological Engineering Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 166. Hualan Biological Engineering Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 167. Hualan Biological Engineering Recent Developments
Table 168. Shanghai RAAS blood products Company Information
Table 169. Shanghai RAAS blood products Description and Major Businesses
Table 170. Shanghai RAAS blood products Antihemophilic Factor Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 171. Shanghai RAAS blood products Antihemophilic Factor Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 172. Shanghai RAAS blood products Recent Developments
Table 173. Key Raw Materials Lists
Table 174. Raw Materials Key Suppliers Lists
Table 175. Antihemophilic Factor Drug Distributors List
Table 176. Antihemophilic Factor Drug Customers List
Table 177. Antihemophilic Factor Drug Market Trends
Table 178. Antihemophilic Factor Drug Market Drivers
Table 179. Antihemophilic Factor Drug Market Challenges
Table 180. Antihemophilic Factor Drug Market Restraints
Table 181. Research Programs/Design for This Report
Table 182. Key Data Information from Secondary Sources
Table 183. Key Data Information from Primary Sources
List of Figures
Figure 1. Antihemophilic Factor Drug Product Picture
Figure 2. Global Antihemophilic Factor Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Antihemophilic Factor Drug Market Share by Type in 2022 & 2029
Figure 4. 250 IU Product Picture
Figure 5. 500 IU Product Picture
Figure 6. 1000 IU Product Picture
Figure 7. 1500 IU Product Picture
Figure 8. 2000 IU Product Picture
Figure 9. 3000 IU Product Picture
Figure 10. 4000 IU Product Picture
Figure 11. Other potencies Product Picture
Figure 12. Global Antihemophilic Factor Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 13. Global Antihemophilic Factor Drug Market Share by Application in 2022 & 2029
Figure 14. Adult
Figure 15. Pediatric
Figure 16. Antihemophilic Factor Drug Report Years Considered
Figure 17. Global Antihemophilic Factor Drug Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Antihemophilic Factor Drug Revenue 2018-2029 (US$ Million)
Figure 19. Global Antihemophilic Factor Drug Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 20. Global Antihemophilic Factor Drug Revenue Market Share by Region (2018-2029)
Figure 21. Global Antihemophilic Factor Drug Sales 2018-2029 ((K Units)
Figure 22. Global Antihemophilic Factor Drug Sales Market Share by Region (2018-2029)
Figure 23. US & Canada Antihemophilic Factor Drug Sales YoY (2018-2029) & (K Units)
Figure 24. US & Canada Antihemophilic Factor Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Europe Antihemophilic Factor Drug Sales YoY (2018-2029) & (K Units)
Figure 26. Europe Antihemophilic Factor Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 27. China Antihemophilic Factor Drug Sales YoY (2018-2029) & (K Units)
Figure 28. China Antihemophilic Factor Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 29. Asia (excluding China) Antihemophilic Factor Drug Sales YoY (2018-2029) & (K Units)
Figure 30. Asia (excluding China) Antihemophilic Factor Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 31. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales YoY (2018-2029) & (K Units)
Figure 32. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue YoY (2018-2029) & (US$ Million)
Figure 33. The Antihemophilic Factor Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 34. The Top 5 and 10 Largest Manufacturers of Antihemophilic Factor Drug in the World: Market Share by Antihemophilic Factor Drug Revenue in 2022
Figure 35. Global Antihemophilic Factor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 36. Global Antihemophilic Factor Drug Sales Market Share by Type (2018-2029)
Figure 37. Global Antihemophilic Factor Drug Revenue Market Share by Type (2018-2029)
Figure 38. Global Antihemophilic Factor Drug Sales Market Share by Application (2018-2029)
Figure 39. Global Antihemophilic Factor Drug Revenue Market Share by Application (2018-2029)
Figure 40. US & Canada Antihemophilic Factor Drug Sales Market Share by Type (2018-2029)
Figure 41. US & Canada Antihemophilic Factor Drug Revenue Market Share by Type (2018-2029)
Figure 42. US & Canada Antihemophilic Factor Drug Sales Market Share by Application (2018-2029)
Figure 43. US & Canada Antihemophilic Factor Drug Revenue Market Share by Application (2018-2029)
Figure 44. US & Canada Antihemophilic Factor Drug Revenue Share by Country (2018-2029)
Figure 45. US & Canada Antihemophilic Factor Drug Sales Share by Country (2018-2029)
Figure 46. U.S. Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 47. Canada Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 48. Europe Antihemophilic Factor Drug Sales Market Share by Type (2018-2029)
Figure 49. Europe Antihemophilic Factor Drug Revenue Market Share by Type (2018-2029)
Figure 50. Europe Antihemophilic Factor Drug Sales Market Share by Application (2018-2029)
Figure 51. Europe Antihemophilic Factor Drug Revenue Market Share by Application (2018-2029)
Figure 52. Europe Antihemophilic Factor Drug Revenue Share by Country (2018-2029)
Figure 53. Europe Antihemophilic Factor Drug Sales Share by Country (2018-2029)
Figure 54. Germany Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 55. France Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 56. U.K. Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 57. Italy Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 58. Russia Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 59. China Antihemophilic Factor Drug Sales Market Share by Type (2018-2029)
Figure 60. China Antihemophilic Factor Drug Revenue Market Share by Type (2018-2029)
Figure 61. China Antihemophilic Factor Drug Sales Market Share by Application (2018-2029)
Figure 62. China Antihemophilic Factor Drug Revenue Market Share by Application (2018-2029)
Figure 63. Asia Antihemophilic Factor Drug Sales Market Share by Type (2018-2029)
Figure 64. Asia Antihemophilic Factor Drug Revenue Market Share by Type (2018-2029)
Figure 65. Asia Antihemophilic Factor Drug Sales Market Share by Application (2018-2029)
Figure 66. Asia Antihemophilic Factor Drug Revenue Market Share by Application (2018-2029)
Figure 67. Asia Antihemophilic Factor Drug Revenue Share by Region (2018-2029)
Figure 68. Asia Antihemophilic Factor Drug Sales Share by Region (2018-2029)
Figure 69. Japan Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 70. South Korea Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 71. China Taiwan Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 72. Southeast Asia Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 73. India Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 74. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Market Share by Type (2018-2029)
Figure 75. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue Market Share by Type (2018-2029)
Figure 76. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Market Share by Application (2018-2029)
Figure 77. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue Market Share by Application (2018-2029)
Figure 78. Middle East, Africa and Latin America Antihemophilic Factor Drug Revenue Share by Country (2018-2029)
Figure 79. Middle East, Africa and Latin America Antihemophilic Factor Drug Sales Share by Country (2018-2029)
Figure 80. Brazil Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 81. Mexico Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 82. Turkey Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 83. Israel Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 84. GCC Countries Antihemophilic Factor Drug Revenue (2018-2029) & (US$ Million)
Figure 85. Antihemophilic Factor Drug Value Chain
Figure 86. Antihemophilic Factor Drug Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries